Indivisible Partners
ENGN icon

Indivisible Partners’s enGene Therapeutics ENGN Stock Holding History

Indivisible Partners’s Portfolio ENGN Stock Details ENGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$58.9K Buy
+29,446
New +$54.5K ﹤0.01% 743

Other funds holding ENGN

Peapod Lane Capital
Peapod Lane Capital Bedford Hills, New York $134M AUM 63.91% 1-Year Est. Return
PFS Partners
PFS Partners Mine Hill, New Jersey $246M AUM 22.61% 1-Year Est. Return
Covestor
Covestor London, United Kingdom $157M AUM 35.87% 1-Year Est. Return
Farther Finance Advisors
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
SBI Securities
SBI Securities Tokyo, Japan $4.38B AUM 56.37% 1-Year Est. Return

Indivisible Partners's ENGN Position: Q3 2026 in Review

Indivisible Partners opened a new position in enGene Therapeutics (ENGN) in Q3 2026: 29,446 shares worth $58.9K. The stake represents ﹤0.01% of the portfolio and ranks #743 among its holdings.

6 funds tracked by Wall St. Rank hold ENGN as of Q3 2026.

  • Indivisible Partners held 29,446 shares of enGene Therapeutics worth $58.9K as of Q3 2026.
  • enGene Therapeutics was a new Indivisible Partners position in Q3 2026.
  • enGene Therapeutics made up ﹤0.01% of Indivisible Partners's portfolio in Q3 2026, its #743 holding.
  • 6 funds tracked by Wall St. Rank held enGene Therapeutics as of Q3 2026.

Based on Indivisible Partners's 13F filing for Q3 2026, filed 26 Oct 2026.